A Randomized, Placebo-Controlled Trial of Latrepiridine in Huntington Disease

Karl Kieburtz, MD, MPH; Michael P. McDermott, PhD; Tiffini S. Voss, MD; Jody Corey-Bloom, MD, PhD; Lisa M. Deuel, BA; E. Ray Dorsey, MD, MBA; Stewart Factor, DO; Michael D. Geschwind, MD, PhD; Karen Hodgeman, CCRA; Elise Kayson, MS, RNC; Sarah Noomberg, MD, PhD; Michael Pourfar, MD; Karen Rabinowitz, JD; Bernard Ravina, MD, MSCE; Juan Sanchez-Ramos, MD, PhD; Lynn Seely, MD; Francis Walker, MD; Andrew Feigin, MD; and The Dimebon in Subjects With Huntington Disease (DIMOND) Investigators of the Huntington Study Group

Objectives: To evaluate the safety and tolerability of latrepiridine in Huntington disease (HD) and explore its effects on cognition, behavior, and motor symptoms.

Design: Double-blind, randomized, placebo-controlled trial.

Setting: Multicenter outpatient trial.

Participants: Ninety-one participants with mild to moderate HD enrolled at 17 US and UK centers from July 18, 2007, through July 16, 2008.

Intervention: Latrepiridine, 20 mg 3 times daily (n=46), or matching placebo (n=45) for a 90-day treatment period.

Main Outcome Measures: The primary outcome variable was tolerability, defined as the ability to complete the study at the assigned drug dosage. Secondary outcome variables included score changes from baseline to day 90 on the Unified Huntington’s Disease Rating Scale (UHDRS), the Mini-Mental State Examination (MMSE), and the Alzheimer Disease Assessment Scale–cognitive subscale (ADAS-cog).

Results: Latrepiridine was well tolerated (87% of the patients given latrepiridine completed the study vs 82% in the placebo group), and adverse event rates were comparable in the 2 groups (70% in the latrepiridine group and 80% in the placebo group). Treatment with latrepiridine resulted in improved mean MMSE scores compared with stable performance in the placebo group (treatment effect, 0.97 points; 95% confidence interval, 0.10-1.85; P=0.03). No significant treatment effects were seen on the UHDRS or the ADAS-cog.

Conclusions: Short-term administration of latrepiridine is well tolerated in patients with HD and may have a beneficial effect on cognition. Further investigation of latrepiridine is warranted in this population with HD.

Trial Registration: clinicaltrials.gov Identifier: NCT00497159

Arch Neurol. 2010;67(2):154-160

HUNTINGTON DISEASE (HD) is a hereditary neurodegenerative disorder that affects movement, behavior, and cognition and leads to death within 20 years of disease onset. Cognitive impairment occurs early in the disease and deteriorates as HD progresses, contributing to loss of ability to work and perform activities of daily living. No effective treatments are currently available to alter the course of the disease or to improve cognition because tetrabenazine, the only approved therapy for HD, treats only chorea and other motor symptoms.

Abnormal mitochondrial depolarization, which can lead to collapse of the mitochondrial membrane and ultimately neuronal apoptosis, has been implicated in the pathophysiologic progression of HD and other neurodegenerative diseases. Latrepiridine is a synthetic molecule that stabilizes mitochondrial membranes and increases neurite outgrowth to an extent comparable to the maximally effective dose of brain-derived neurotrophic factor in cultured neurons. Improvement in mitochondrial function may prevent apoptosis and also improve the efficiency of dynamic cellular activities, such as firing of action potentials and the maintenance or formation of synapses. Latrepiridine, 20 mg 3 times daily, has been studied in a randomized, double-blind, placebo-controlled trial in patients with mild to moderate Alzheimer's disease.
dementia (AD) and demonstrated significant improvement compared with placebo in cognitive, behavioral, and functional scores at 6 and 12 months. An earlier open-label, dose-escalation study in patients with HD suggested dosages up to 20 mg 3 times daily would be tolerated in this population. We studied the safety and tolerability of latrepirdine with mild to moderate HD.

**Methods**

**Study Organization**

This multicenter clinical trial was managed through the Huntington Study Group (HSG) and sponsored by Medivation Inc (San Francisco, California), which supplied study drug and matching placebo. The protocol and consent forms were approved by the University of Rochester institutional review board and the institutional review board at each participating site. The Steering Committee and an independent Data and Safety Monitoring Board monitored the safety, data integrity, and conduct of the trial.

**Study Participants**

Participants were men and women 29 years or older with a clinical diagnosis of HD and either a positive family history or a CAG repeat length of 36 or greater. Eligible patients were ambulatory, were living in the community, did not require skilled nursing care, and had a Unified Huntington’s Disease Rating Scale (UHDRS) total functional capacity score of 5 or higher at baseline. Because some animal studies raised a potential concern about increased risk of seizures and clinical experience in this population was limited, all participants agreed to comply with general seizure precautions. Participants taking psychotropic medications were required to be taking a stable dosage for at least 30 days before the baseline visit. Participants agreed to use 2 contraception methods; women who were pregnant or nursing were excluded. Other exclusion criteria were a history of seizures, cardiovascular disease, QTc intervals greater than 450 milliseconds, recent investigational drug exposure, unstable medical or psychiatric illness, active peptic ulcer disease, bladder obstruction, human immunodeficiency virus, hepatitis B or C, or significant laboratory abnormalities. The use of cholinesterase inhibitors, N-methyl-D-aspartate antagonists, all forms of dextromethorphan (including hydrobromide and hydrochloride formulations), nonselective antihistamines, lithium, or clonidine was prohibited.

**Study Design and Randomization Procedure**

Participants received study drug (latrepirdine at a dosage of 20 mg or placebo 3 times daily) for 90 days followed by a 14-day safety observation period (total trial duration, 104 days). Eligible participants were randomized in a 1:1 allocation to the 2 treatment arms, and the permuted-block randomization was stratified by site. A nonmasked programmer from the University of Rochester, independent of the other study staff, generated the masked randomization code. Sites enrolled participants via a secure Web page that provided the randomized study drug kit numbers. Participants, investigators, HSG study staff, and sponsor were masked to study group assignment.

**Study Intervention**

Participants initiated use of the study drug with a single 10-mg dose on day 1 followed by a dosage of 10 mg 3 times daily for 6 days, then titrated up to 20 mg 3 times daily for the remainder of the 90-day treatment period. The study drug was formulated as a tablet and encapsulated to maintain masking. Latrepirdine and matching placebo were supplied by QS Pharma (Boothwyn, Pennsylvania).

**Study Procedures**

All participants gave written documentation of informed consent before any study-related procedure. Screening occurred within 21 days of the baseline visit, and participants were enrolled after an assessment of eligibility criteria. Before receiving study drug on day 1, physical examination, vital sign measurement, laboratory testing, electrocardiography (ECG), pregnancy test if indicated, the UHDRS, the Mini-Mental State Examination (MMSE), and the Alzheimer Disease Assessment Scale–cognitive subscale (ADAS-cog) were performed. Safety assessments (including assessment of adverse events, physical examination, vital sign measurements, ECG, urinalysis, and serum chemical, hematologic, and coagulation tests) were conducted in person on days 15, 30, 60, 90, and 104 and by telephone on days 2, 45, and 75. Efficacy assessments were performed on days 30 (UHDRS only), 60, and 90 (UHDRS, MMSE, and ADAS-cog). The final visit occurred 2 weeks after completion of the treatment period (day 104) and included the UHDRS and safety assessments.

**Outcome Measures**

The primary outcome measure was the ability of a participant to complete the 90-day treatment period on the assigned dosage of study drug (tolerability). Safety outcomes were assessed by inquiring about adverse events at each visit and telephone contact, as well as examining changes in laboratory values, vital signs, or ECGs. Adverse events, including serious adverse events, were reviewed throughout the trial by the medical monitor, the Steering Committee, the sponsor, and the Data and Safety Monitoring Board.

Efficacy outcome measures included changes from baseline to day 90 in the UHDRS, MMSE, and ADAS-cog scores. The UHDRS is a comprehensive scale used to assess motor function, cognition, behavior, and functional capacity. Outcomes include the total motor score, behavioral frequency score, motor frequency × severity score, functional assessment, independence scale, and total functional capacity. For motor and behavioral assessments, higher scores indicate worsening; for the functional outcomes, lower scores indicate worsening. Cognitive performance in the UHDRS is assessed by means of the verbal fluency test, the symbol digit modalities test, and the Stroop interference test. The MMSE is a common, validated screening instrument that is used as a general measure of cognitive function; lower scores indicate greater impairment. The ADAS-cog used in this study contains the standard 11-item scale developed for use in AD plus 3 additional items added to increase evaluation of executive function. Higher scores on the ADAS-cog indicate greater impairment.

**Statistical Analysis**

The primary tolerability outcome and occurrences of individual adverse events, abnormal laboratory test results, and abnormal ECG results were compared between the latrepirdine
and placebo groups by means of either χ² tests or Fisher exact tests, as appropriate. Analyses of safety outcomes included all participants who received at least 1 dose of the study drug.

The analyses of the efficacy outcomes were exploratory. Changes from baseline to day 90 for the UHDRS, MMSE, and ADAS-cog outcomes were compared between the treatment groups by means of repeated-measures analysis of covariance models that included treatment group, time, the interaction between treatment group and time, and the baseline value of the outcome variable. The analyses of the efficacy outcomes were performed with a modified intention-to-treat paradigm and included all participants who received at least 1 dose of study drug and had at least 1 postbaseline evaluation.

**RESULTS**

**PARTICIPANT ENROLLMENT**

From July 18, 2007, through July 16, 2008, 113 potential participants were identified and evaluated. Of these, 91 were eligible and were enrolled and randomized to either the latrepirdine or placebo group (Figure 1). One participant (assigned to the placebo group) was withdrawn from the study after randomization but before receiving the study drug because of ineligibility. Demographic characteristics were similar between groups at baseline, although the placebo group had a somewhat higher percentage of women (60%) than the latrepirdine group (43%) (Table 1). Ninety-six percent of patients treated with latrepirdine and 89% of those treated with placebo were taking at least 1 concomitant medication. The use of any psychotropic medication was 74% in the latrepirdine group and 68% in the placebo group.

**TOLERABILITY**

Latrepirdine and placebo were both generally well tolerated, with 40 of the 46 participants who took latrepirdine (87%) completing the study with the 60-mg/d dosage of drug vs 36 of the 44 participants in the placebo group (82%); study completion rates did not differ
between groups. Of the 6 participants who took latrepirdine and did not complete the study, 5 discontinued the study because of adverse events (loss of consciousness, rash, headache and urinary difficulty, supraventricular tachycardia, diagnosis unknown) and 1 was withdrawn because of a protocol violation (participant was already medicated). Of the 7 participants who took placebo and did not complete the study, 5 discontinued the study because of adverse events (pelvic fracture, cancer, irritability, ECG T-wave inversion, increased QTc interval), 1 was withdrawn because of a protocol violation (participant was taking excluded medication), and 1 withdrew consent. In addition, 1 participant in the placebo group completed the study at a reduced dosage (10 mg 3 times daily) because of worsened speech.

### SAFETY

Overall, 70% of participants who took latrepirdine and 80% of those who took placebo reported an adverse event. Thirty-three percent of participants who took latrepirdine and 43% of those who took placebo reported an adverse event of moderate or severe intensity. The most common adverse events are listed by treatment group in **Table 2**. Falling was the most common event, reported in 9% of the latrepirdine group and 16% of the placebo group. No clinically relevant differences in laboratory test results, ECG results, or vital sign measurements were noted between the treatment groups.

One serious adverse event occurred in the latrepirdine group (loss of consciousness), and 3 serious adverse events occurred in 2 participants in the placebo group (pelvic fracture in 1; myocardial infarction and breast cancer in another). The loss of consciousness was transient and did not recur, and the cause of the event remains unclear despite subsequent cardiac and neurologic evaluation. One participant in the latrepirdine group had a cluster of signs and symptoms, specifically fatigue, irritability, weight loss, and confusion, with associated neutrophilia, thrombocytosis, anemia, and elevated aspartate aminotransferase and alanine aminotransferase levels. The syndrome resolved without definitive intervention, and its cause and relation to study drug remain unclear.

### COGNITIVE OUTCOMES

The number of participants included in the analysis of efficacy outcomes ranged from 81 (ADAS-cog) to 87 (UHDRS) (**Table 3**). During the 90-day treatment period, treatment with latrepirdine resulted in mean improvement on the MMSE compared with placebo (treatment effect, 0.97 points; 95% confidence interval, .05).

---

**Table 2. Adverse Events Reported by More Than 5% of Participants in Either Treatment Group**

<table>
<thead>
<tr>
<th>Adverse Events</th>
<th>No. (%) of Study Participants</th>
<th>Latrepirdine (n=46)</th>
<th>Placebo (n=44)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Falls</td>
<td>4 (9)</td>
<td>7 (16)</td>
<td>.35</td>
<td></td>
</tr>
<tr>
<td>Headache</td>
<td>7 (15)</td>
<td>3 (7)</td>
<td>.32</td>
<td></td>
</tr>
<tr>
<td>Dizziness</td>
<td>3 (7)</td>
<td>6 (14)</td>
<td>.31</td>
<td></td>
</tr>
<tr>
<td>Nausea</td>
<td>3 (7)</td>
<td>5 (11)</td>
<td>.48</td>
<td></td>
</tr>
<tr>
<td>Chorea</td>
<td>3 (7)</td>
<td>3 (7)</td>
<td>&gt;.99</td>
<td></td>
</tr>
<tr>
<td>Depression</td>
<td>2 (4)</td>
<td>3 (7)</td>
<td>.67</td>
<td></td>
</tr>
<tr>
<td>Nasopharyngitis</td>
<td>2 (4)</td>
<td>3 (7)</td>
<td>.67</td>
<td></td>
</tr>
<tr>
<td>Somnolence</td>
<td>3 (7)</td>
<td>1 (2)</td>
<td>.62</td>
<td></td>
</tr>
<tr>
<td>Irritability</td>
<td>1 (2)</td>
<td>3 (7)</td>
<td>.36</td>
<td></td>
</tr>
<tr>
<td>Increased electrocardiogram</td>
<td>0 (0)</td>
<td>3 (7)</td>
<td>.11</td>
<td></td>
</tr>
<tr>
<td>QTc interval</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diarrhea</td>
<td>0 (0)</td>
<td>3 (7)</td>
<td>.11</td>
<td></td>
</tr>
</tbody>
</table>

**Table 3. Changes From Baseline to Day 90 in Efficacy Outcome Measures**

<table>
<thead>
<tr>
<th>Outcome Measure</th>
<th>Mean (SD)</th>
<th>Treatment Effect for Latrepirdine vs Placebo (95% Confidence Interval)a</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>UHDRS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Verbal fluencyb</td>
<td>3.78 (1.04)</td>
<td>-1.98 (−4.94 to 0.98)</td>
<td>.19</td>
</tr>
<tr>
<td>Symbol digit modalities testb</td>
<td>1.06 (0.71)</td>
<td>1.20 (−0.82 to 3.22)</td>
<td>.24</td>
</tr>
<tr>
<td>Stroop color namingb</td>
<td>0.44 (1.16)</td>
<td>-0.14 (−3.42 to 3.13)</td>
<td>.93</td>
</tr>
<tr>
<td>Stroop word readingb</td>
<td>−1.36 (1.53)</td>
<td>1.68 (−2.64 to 6.00)</td>
<td>.44</td>
</tr>
<tr>
<td>Stroop interferencesb</td>
<td>−0.63 (0.97)</td>
<td>-1.38 (−4.13 to 1.38)</td>
<td>.32</td>
</tr>
<tr>
<td>Behavioral frequencyc</td>
<td>−0.86 (0.54)</td>
<td>-0.90 (−2.44 to 0.65)</td>
<td>.25</td>
</tr>
<tr>
<td>Behavioral frequency × severityc</td>
<td>−1.47 (1.26)</td>
<td>-2.02 (−5.60 to 1.57)</td>
<td>.27</td>
</tr>
<tr>
<td>Total motorc</td>
<td>−0.17 (1.11)</td>
<td>-0.39 (−3.54 to 2.76)</td>
<td>.81</td>
</tr>
<tr>
<td>Total functional capacityb</td>
<td>−0.04 (0.15)</td>
<td>-0.06 (−0.47 to 0.36)</td>
<td>.79</td>
</tr>
<tr>
<td>Functional assessmentb</td>
<td>0.01 (0.25)</td>
<td>-0.10 (−0.82 to 0.62)</td>
<td>.79</td>
</tr>
<tr>
<td>Independence scaleb</td>
<td>−0.48 (0.77)</td>
<td>0.10 (−2.09 to 2.29)</td>
<td>.93</td>
</tr>
<tr>
<td>MMSEb</td>
<td>0.86 (0.31)</td>
<td>0.97 (0.10 to 1.85)</td>
<td>.03d</td>
</tr>
<tr>
<td>ADAS-coc</td>
<td>−1.15 (0.82)</td>
<td>-0.31 (−2.64 to 2.02)</td>
<td>.79</td>
</tr>
</tbody>
</table>

**Table 3. Changes From Baseline to Day 90 in Efficacy Outcome Measures**

<table>
<thead>
<tr>
<th>Outcome Measure</th>
<th>Mean (SD)</th>
<th>Treatment Effect for Latrepirdine vs Placebo (95% Confidence Interval)a</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>UHDRS</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Abbreviations:** ADAS-cog, Alzheimer Disease Assessment Scale–cognitive subscale; MMSE, Mini-Mental State Examination; UHDRS, Unified Huntington’s Disease Rating Scale.

a Treatment effect is the difference (latrepirdine−placebo) between the adjusted group mean changes calculated from a repeated-measures analysis of covariance model.

b Positive mean change indicates improvement.

c Negative mean change indicates improvement.

d P<.05.

(Reprinted) ARCH NEUROL/VOL 67 (NO. 2), FEB 2010 WWW.ARCHNEUROL.COM

©2010 American Medical Association. All rights reserved.
Latrepirdine is an investigational drug that may improve cognition in patients with AD. It has a mechanism of action distinct from other drugs, such as cholinesterase inhibitors and N-methyl-D-aspartate receptor antagonists, currently approved to treat neurodegenerative cognitive disorders. Nonclinical data available to date suggest that the mechanism of action of latrepirdine is to enhance mitochondrial function in the setting of cellular stress. Mitochondrial dysfunction has been documented in several neurodegenerative diseases, such as AD, HD, and Parkinson disease. Given the mechanism of action of latrepirdine and the lack of approved therapies for cognitive impairment in HD, we elected to study latrepirdine in HD.

The current randomized, double-blind, placebo-controlled study was undertaken to determine the tolerability of latrepirdine in patients with HD. Our data show that latrepirdine, at a dosage of 20 mg 3 times daily, was well tolerated compared with placebo for patients with HD during a 90-day treatment period. Headache and somnolence were observed more commonly in those taking latrepirdine than in those taking placebo in this study. This finding is distinct from the experience in AD, for which the adverse events reported more commonly in patients with AD treated with latrepirdine compared with placebo were dry mouth, depressed mood or depression, and hyperhidrosis. The reasons for these differences are not known but may relate to differences in study populations, concomitant medications, or sample size. Both studies reported no increase in adverse events or serious adverse events in patients treated with latrepirdine compared with those treated with placebo. Because the treatment period in this study was 90 days, we cannot evaluate the risk for adverse effects that may emerge after longer exposure; however, data in AD suggest latrepirdine is well tolerated for up to 12 months.

Although the primary end points of this study were safety and tolerability, we had an a priori interest in the potential effects of latrepirdine on cognition and behavior, given its mechanism of action and its effects as previously demonstrated in patients with AD. We therefore included several measures of cognition and behavior in...
our assessment battery and used a modified form of the ADAS-cog to attempt to capture executive function more thoroughly. The study was not designed to detect a minimally clinically significant effect on any of the efficacy measures; however, we were better able to detect small treatment differences on the MMSE than the UHDRS or ADAS-cog because of reduced variability in the MMSE. The MMSE results suggest that latrepirdine may benefit cognition in HD, although these effects were not consistently supported by the other cognitive assessments.

A significant finding on the MMSE was surprising, given that the MMSE is generally considered a relatively insensitive measure of cognitive function. However, there are several possible explanations for this unexpected discrepancy, such as variation in psychometric properties, the specific cognitive domains assessed by each outcome, and ability to detect clinically relevant short-term cognitive change in HD. For example, the MMSE provides a broader assessment of cognition than the other end points assessed. Although not developed specifically for the type of impairment commonly seen in patients with HD, it is highly stable during a 6-month to 12-month period with low variability in patients who were untreated (unpublished data, available on request). These characteristics could enhance our ability to detect an intervention that resulted in improvement over baseline compared with the other measures. The UHDRS cognitive tests were selected to track the long-term natural history of cognitive decline in HD rather than the effect of a short-term intervention. These tests are also limited by the relatively narrow range of cognitive function assessed. The ADAS-cog provides a broader assessment of cognitive function and was developed for use in short-term symptomatic studies; however, the individual domains were chosen to be sensitive to cognitive changes in AD and may not be as relevant to the types of impairment in HD. An effect of multiple comparisons cannot be excluded; however, the MMSE effect is comparable to that previously demonstrated in patients with AD. It is unknown whether MMSE scores would continue to improve beyond 90 days, although participants treated with latrepirdine demonstrated continued improvement in cognition during a 6-month to 12-month period in the AD trial on both the MMSE and the ADAS-cog. These exploratory results on the MMSE are worthy of further evaluation in a randomized trial of treatment efficacy because the trial was not designed to detect a minimally clinically significant effect on any of the efficacy measures. The results for the UHDRS behavioral assessments showed qualitative improvement in the latrepirdine group relative to the placebo group. These results are also consistent with the significant effect of latrepirdine in improving behavioral symptoms observed in patients with AD.

Taken together, our data suggest that latrepirdine, at a dosage of 20 mg 3 times daily, is well tolerated for 90 days in patients with HD and may have a beneficial effect on cognition. Future studies of latrepirdine are planned to further evaluate the effect of latrepirdine on the cognitive and behavioral symptoms of HD.

Accepted for Publication: September 24, 2009.

Author Affiliations: Departments of Neurology (Dr Kieburtz, McDermott, Voss, Dorsey, and Ravina and Ms Deuel) and Biostatistics and Computational Biology (Dr McDermott) and Clinical Trials Coordination Center (Ms Hodgeman, Kayson, and Rabinowitz); School of Medicine and Dentistry, University of Rochester, Rochester, New York; Department of Neurosciences, University of California, San Diego (Dr Corey-Bloom); Department of Neurology, Emory University, Atlanta, Georgia (Dr Factor); Memory and Aging Center, University of California, San Francisco (Dr Geschwind) and Medivation Inc, San Francisco (Drs Noonberg and Seely); Departments of Neurology, North Shore–Long Island Jewish Health System, Manhasset, New York (Drs Pourfar and Feigin), University of South Florida College of Medicine, Tampa (Dr Sanchez-Ramos), and Wake Forest University School of Medicine, Winston-Salem, North Carolina (Dr Walker). Dr Voss is currently with the Department of Neurology, University of Virginia–Charlottesville.

Correspondence: Tiffini S. Voss, MD, University of Virginia, Department of Neurology, PO Box 900394, Charlottesville, VA 22908 (tv4e@virginia.edu).

Author Contributions: All authors had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Kieburtz, McDermott, Hodges, Kayson, Rabinowitz, Ravina, Seely, and Feigin. Acquisition of data: McDermott, Voss, Corey-Bloom, Deuel, Dorsey, Factor, Geschwind, Hodges, Kayson, Noonberg, Pourfar, Rabinowitz, Ravina, Sanchez-Ramos, Seely, Walker, and Feigin. Analysis and interpretation of data: Kieburtz, McDermott, Voss, Corey-Bloom, Deuel, Dorsey, Factor, Geschwind, Noonberg, Pourfar, Ravina, Sanchez-Ramos, Seely, Walker, and Feigin. Drafting of the manuscript: Kieburtz, McDermott, Voss, and Ravina. Critical revision of the manuscript for important intellectual content: Kieburtz, McDermott, Voss, Corey-Bloom, Deuel, Dorsey, Factor, Geschwind, Hodges, Kayson, Noonberg, Pourfar, Rabinowitz, Ravina, Sanchez-Ramos, Seely, Walker, and Feigin. Statistical analysis: McDermott, Ravina, and Feigin. Obtained funding: Kieburtz and Feigin. Administrative, technical, and material support: Kieburtz, Hodges, Kayson, Noonberg, Rabinowitz, Seely, and Feigin. Study supervision: Kieburtz, McDermott, Voss, Hodges, Kayson, Noonberg, Ravina, Sanchez-Ramos, and Feigin.

Funding/Support: This study was funded by a grant from Medivation Inc to the University of Rochester and in turn through subcontracts to the participating research sites.

Financial Disclosure: None of the HSG investigators has equity interest or has received personal remuneration from the sponsoring company since the initiation of the study. Through subcontract with the University of Rochester, Dr Kieburtz has received research grant support from the National Institutes of Health, the Michael J. Fox Foundation, Medivation Inc, NeuroSearch, and Pfizer Inc. He has served as a consultant to the Food and Drug Admin-


**Correction**

Error in Byline, Affiliation Footnote, Drug Nomenclature, and Figure 1. In the Clinical Trial titled "A Randomized, Placebo-Controlled Trial of Latrepirdine in Huntington Disease" by the Huntington Study Group DIMOND Investigators, published in the February issue of the *Archives* (2010;67(2):154-160), the byline was incorrectly presented, the affiliation footnote was incorrect, and the drug nomenclature needed further clarification. The byline should have read “The Huntington Disease Study Group DIMOND Investigators*. The affiliation footnote should have read **“*This report was prepared on behalf of The Huntington Study Group DIMOND Investigators by Karl Kieburtz, MD, MPH; Michael P. McDermott, PhD; Tiffini S. Voss, MD; Jody Corey-Bloom, MD, PhD; Lisa M. Deuel, BA; E. Ray Dorsey, MD, MBA; Stewart Factor, DO; Michael D. Geschwind, MD, PhD; Karen Hodgeman, CCRA; Elise Kayson, MS, RNC; Sarah Noonberg, MD, PhD; Michael Pourfar, MD; Karen Rabinowitz, JD; Bernard Ravina, MD, MSCE; Juan Sanchez-Ramos, MD, PhD; Lynn Seely, MD; Francis Walker, MD; and Andrew Feigin, MD." The affiliation footnote should have noted the group information and should have read: “*Group Information: A complete list of The Huntington Study Group DIMOND Investigators* appears at the end of this article. To clarify the drug nomenclature at first mention of latrepirdine in the second paragraph of the introduction, the copy should have read: “latrepirdine (common name, dimebolin) is a synthetic molecule...” In Figure 1, the drug name “dimebolin” in the second box on the far right-hand side should have read “latrepirdine.”